Sandoz launches generic Tobi

PRINCETON, N.J. — Sandoz on Monday announced the introduction of tobramycin inhalation solution, USP into the U.S. market. The drug is an authorized generic version of Tobi from Novartis.



The drug is used for the management of cystic fibrosis in patients whose lungs contain bacteria called P. aeruginosa, the company said. Cystic fibrosis is a life-threatening disease that affects the lungs and digestive system. It's estimated that 30,000 children and adults in the United States suffer from the disease.



"We are proud to bring the authorized generic of Tobi to the patients with cystic fibrosis,” said Peter Goldschmidt, president of Sandoz US. “As part of the Novartis Group, we work together to increase patient access to leading treatments in the most efficient and effective way possible.”



Sales for the the branded version of tobramycin inhalation solution, USP were approximately $241 million for the 12 months ended April 2014, according to IMS Health. Sandoz will be marketing the drug in 300-mg single-dose ampules, the same size and strength that is currently being marketed by the brand.